2023 - Research.com Medicine in Spain Leader Award
2022 - Research.com Best Scientist Award
Josep M. Llovet focuses on Hepatocellular carcinoma, Internal medicine, Sorafenib, Carcinoma and Surgery. Josep M. Llovet studies Liver cancer, a branch of Hepatocellular carcinoma. His Internal medicine research includes elements of Gastroenterology and Oncology.
His study looks at the intersection of Sorafenib and topics like Regorafenib with Lenvatinib and Cabozantinib. His Carcinoma research integrates issues from Percutaneous ethanol injection, Survival rate, Stage, Hepatectomy and Receiver operating characteristic. His Surgery research focuses on Liver function and how it connects with Cirrhosis.
Hepatocellular carcinoma, Internal medicine, Oncology, Cancer research and Sorafenib are his primary areas of study. His Hepatocellular carcinoma research focuses on Surgery and how it relates to Liver function. He focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Gastroenterology and, in certain cases, Hepatitis C virus.
His Oncology research incorporates themes from Biomarker, Regorafenib and Disease. Josep M. Llovet combines subjects such as Wnt signaling pathway, PI3K/AKT/mTOR pathway, Immune system and Bioinformatics with his study of Cancer research. Josep M. Llovet interconnects Response Evaluation Criteria in Solid Tumors and Hazard ratio in the investigation of issues within Sorafenib.
Josep M. Llovet mostly deals with Hepatocellular carcinoma, Internal medicine, Cancer research, Oncology and Liver cancer. He has researched Hepatocellular carcinoma in several fields, including Biomarker, Cancer and Carcinoma. In his research, Etiology is intimately related to Gastroenterology, which falls under the overarching field of Internal medicine.
His study in Cancer research is interdisciplinary in nature, drawing from both Wnt signaling pathway, Steatohepatitis, Epigenetics and Immune system. His Oncology research is multidisciplinary, incorporating elements of Clinical endpoint and Disease. His research integrates issues of Platelet, Transcriptome and ARID1A in his study of Liver cancer.
Josep M. Llovet focuses on Hepatocellular carcinoma, Internal medicine, Oncology, Cancer research and Carcinoma. His studies deal with areas such as Cancer and General surgery as well as Hepatocellular carcinoma. Sorafenib and Clinical endpoint are the subjects of his Internal medicine studies.
The study incorporates disciplines such as Biomarker, Advanced stage, Clinical trial and Disease in addition to Oncology. In general Cancer research study, his work on Liver cancer often relates to the realm of CCL5, thereby connecting several areas of interest. His work deals with themes such as Gene mutation, BCLC Stage, ARID1A, Tumor progression and Telomerase reverse transcriptase, which intersect with Carcinoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard.
The New England Journal of Medicine (2008)
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle;Alejandro Forner;Josep M. Llovet;Vincenzo Mazzaferro.
Journal of Hepatology (2018)
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Jordi Bruix;Morris Sherman;Josep M Llovet;Michel Beaugrand.
Journal of Hepatology (2001)
PROGNOSIS OF HEPATOCELLULAR CARCINOMA : THE BCLC STAGING CLASSIFICATION
Josep M. Llovet;Concepció Brú;Jordi Bruix.
Seminars in Liver Disease (1999)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Josep M Llovet;Maria Isabel Real;Xavier Montaña;Ramon Planas.
The Lancet (2002)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Josep M. Llovet;Jordi Bruix.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito.
The Lancet (2017)
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet;Michel Ducreux;Riccardo Lencioni;Adrian M. Di Bisceglie.
Josep M Llovet;Robin Kate Kelley;Augusto Villanueva;Amit G Singal.
Nat Rev Dis Primers (2021)
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
Josep M. Llovet;Josep Fuster;Jordi Bruix.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: